Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
Femasys Inc. (NASDAQ: FEMY) announces the issuance of U.S. Patent No. 12,12796 by the USPTO for its FemBloc® permanent birth control device. The patent, expiring no earlier than 2039, strengthens the company's intellectual property position for its leading therapeutic product candidate. This adds to Femasys' portfolio of over 180 patents globally, protecting their suite of products including FemaSeed® for infertility treatment and diagnostic products FemVue®, FemCath®, FemCerv®, and FemChec®. The company is currently enrolling subjects in FemBloc's pivotal clinical trial.
Femasys Inc. (NASDAQ: FEMY) annuncia l'emissione del Brevetto Statunitense n. 12,12796 da parte dell'USPTO per il suo dispositivo di controllo permanente della fertilità FemBloc®. Il brevetto, che scadrà non prima del 2039, rafforza la posizione di proprietà intellettuale dell'azienda per il suo principale candidato terapeutico. Questo si aggiunge al portafoglio di oltre 180 brevetti a livello globale di Femasys, che protegge la loro gamma di prodotti tra cui FemaSeed® per il trattamento dell'infertilità e i prodotti diagnostici FemVue®, FemCath®, FemCerv® e FemChec®. Al momento, l'azienda sta arruolando soggetti per lo studio clinico pivotale di FemBloc.
Femasys Inc. (NASDAQ: FEMY) anuncia la emisión de la Patente de EE. UU. No. 12,12796 por parte de la USPTO para su dispositivo de control de natalidad permanente FemBloc®. La patente, que expirará no antes de 2039, refuerza la posición de propiedad intelectual de la compañía para su principal candidato terapéutico. Esto se suma al portafolio de más de 180 patentes a nivel mundial de Femasys, protegiendo su gama de productos, incluyendo FemaSeed® para el tratamiento de la infertilidad y los productos de diagnóstico FemVue®, FemCath®, FemCerv® y FemChec®. Actualmente, la empresa está reclutando sujetos para el ensayo clínico pivotal de FemBloc.
Femasys Inc. (NASDAQ: FEMY)는 FemBloc® 영구 피임 장치에 대해 USPTO에서 미국 특허 번호 12,12796을 발급받았다고 발표했습니다. 2039년 이전에 만료되지 않는 이 특허는 회사의 주요 치료 제품 후보에 대한 지적 재산권 지위를 강화합니다. 이는 Femasys의 180개 이상의 글로벌 특허 포트폴리오에 추가되어 불임 치료를 위한 FemaSeed®와 진단 제품 FemVue®, FemCath®, FemCerv®, FemChec®를 보호합니다. 현재 회사는 FemBloc의 주요 임상 시험에 피험자를 모집하고 있습니다.
Femasys Inc. (NASDAQ: FEMY) annonce l'octroi du Brevet américain n° 12,12796 par l'USPTO pour son dispositif de contrôle permanent des naissances FemBloc®. Ce brevet, qui expirera au plus tôt en 2039, renforce la position de la société en matière de propriété intellectuelle pour son principal candidat thérapeutique. Cela s'ajoute au portefeuille de plus de 180 brevets de Femasys à l'échelle mondiale, protégeant leur gamme de produits, y compris FemaSeed® pour le traitement de l'infertilité et les produits de diagnostic FemVue®, FemCath®, FemCerv® et FemChec®. L'entreprise recrute actuellement des sujets pour l'essai clinique pivot de FemBloc.
Femasys Inc. (NASDAQ: FEMY) kündigt die Erteilung des US-Patents Nr. 12,12796 durch das USPTO für ihr FemBloc® dauerhaftes Verhütungsgerät an. Das Patent, das nicht vor 2039 abläuft, stärkt die Position des Unternehmens in Bezug auf geistiges Eigentum für seinen führenden therapeutischen Produktkandidaten. Dies ergänzt das Portfolio von Femasys mit über 180 Patenten weltweit, das ihre Produktreihe schützt, einschließlich FemaSeed® zur Behandlung von Unfruchtbarkeit und Diagnosetools FemVue®, FemCath®, FemCerv® und FemChec®. Das Unternehmen rekrutiert derzeit Probanden für die entscheidende klinische Studie von FemBloc.
- New patent protection until 2039 for FemBloc device
- Strong IP portfolio with over 180 global patents
- Ongoing pivotal clinical trial enrollment for FemBloc
- None.
Insights
The issuance of U.S. Patent No. 12,12796 for FemBloc® represents a significant intellectual property milestone for Femasys, extending protection until at least 2039. This patent strengthens the company's position in the female permanent birth control market, where non-surgical alternatives are The patent complements Femasys' extensive portfolio of over 180 global patents across their women's health product line.
The development of FemBloc® addresses a important market gap for non-surgical permanent contraception, particularly following the discontinuation of Essure. With the product currently in pivotal clinical trials, this patent protection significantly enhances its commercial viability. The company's strategic focus on expanding their IP portfolio across both therapeutic and diagnostic products demonstrates a comprehensive approach to women's healthcare market penetration.
FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control
ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 12,12796 covering FemBloc® permanent birth control. This further strengthens Femasys’ intellectual property position and coverage for FemBloc, the Company’s leading therapeutic product candidate.
The issued patent has an anticipated expiration in 2039 at the earliest. Femasys intends to continue to prosecute additional patent applications to further enhance its existing patent portfolio protecting FemBloc, along with the Company’s existing available therapeutic product, FemaSeed® intratubal insemination for infertility treatment, and diagnostic products, FemVue®, FemCath®, FemCerv®, and FemChec®.
“The issuance of claims for the FemBloc permanent birth control is another important milestone in protecting the commercial potential for this novel, non-surgical contraceptive option for women seeking a permanent birth control solution, which is currently enrolling subjects in its pivotal clinical trial,” stated Kathy Lee-Sepsick, CEO of Femasys. “Expansion of our patent portfolio, which consists of over 180 patents globally, demonstrates our continued unwavering commitment to protecting the innovation and commercial opportunity of our entire suite of products for women seeking better and more accessible options.”
About FemBloc
FemBloc® is a first-of-its-kind, nonsurgical, non-implant, in-office solution in its late-stage of clinical development for permanent birth control. It is intended to be a safer option for women estimated at approximately half the cost of the long-standing surgical alternative by eliminating the need for anesthesia, incisions, and permanent implants. FemBloc has the potential to offer women a convenient, accessible, and reliable option for those seeking permanent birth control. For over 100 years there has been stagnant innovation for permanent birth control which could lead to a
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® MINI for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasys.com
Media Contact:
Kati Waldenburg
Media@femasys.com
FAQ
When does Femasys' (FEMY) new FemBloc patent expire?
How many patents does Femasys (FEMY) currently hold globally?
What is the current development status of Femasys' (FEMY) FemBloc device?
What products are covered in Femasys' (FEMY) patent portfolio?
